To compare the efficacy amd safety of Tarlatamab and durvalumab with durvalumab alone on prolonging overall survival
Key inclusion criteria
Histologically or cytologically documented estensive-stage disease IV, SCLC or T3 to T4 due to multiple lung nodules that are too extensive of have tumor/nodal volume that is too large to be encompassed in a tolerable radiation plan.
Completed 4 cycles of platinum-etoposide chemotherapy with concurrent durvalumab as first line treatment, without disease progression
ECOG status of 0 or 1
Key exclusion criteria
Symptomatic central nervous system metastases, or leptomeningeal disease
Systemic corticosteroid therapy of any other form of immunosuppresiive therapy within 14 days prior to first dose of study treatment
